Oral cannabis produced higher urine drug test concentrations than vaporized cannabis

In a controlled study of 21 infrequent cannabis users, oral cannabis triggered positive urine tests 97.6% of the time versus 59.5% for vaporized cannabis at standard workplace cutoffs.

Sholler, Dennis J et al.·Journal of analytical toxicology·2022·Moderate EvidenceRandomized Controlled Trial
RTHC-04218Randomized Controlled TrialModerate Evidence2022RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Randomized Controlled Trial
Evidence
Moderate Evidence
Sample
N=11

What This Study Found

Using federal workplace drug-testing criteria (50 ng/mL screening, 15 ng/mL confirmation), urine specimens tested positive for THC-COOH in 97.6% of oral cannabis sessions versus 59.5% of vaporized sessions at active THC doses.

Key Numbers

21 participants. Peak concentrations occurred at 5-6 hours (oral) and 4 hours (vaporized). At active doses, 97.6% of oral sessions and 59.5% of vaporized sessions produced positive results at standard federal cutoffs. Oral administration produced quantitatively higher maximum concentrations for all detected analytes.

How They Did This

Double-blind, six-session study of 21 infrequent cannabis users (11 men, 10 women). Participants ingested cannabis brownies (0, 10, 25 mg THC) and inhaled vaporized cannabis (0, 5, 20 mg THC). Urinary concentrations of 9 cannabinoid analytes measured at baseline and for 8 hours.

Why This Research Matters

With vaping and edibles now common methods of cannabis consumption, understanding how different administration routes affect drug testing has direct implications for workplace testing policies and legal proceedings.

The Bigger Picture

Drug testing protocols were designed around smoked cannabis. As consumption methods diversify, the detection characteristics of each method need to be understood to ensure testing policies remain fair and accurate.

What This Study Doesn't Tell Us

Only 21 participants, all infrequent users. The 8-hour window may not capture the full excretion profile. Results may not generalize to frequent users who have accumulated THC stores.

Questions This Raises

  • ?Should workplace drug testing cutoffs be adjusted to account for consumption method?
  • ?Could 11-OH-THC serve as a better confirmatory analyte for distinguishing legal from illicit cannabis products?
  • ?How do these profiles differ in frequent users?

Trust & Context

Key Stat:
97.6% positive (oral) vs 59.5% positive (vaporized) at standard cutoffs
Evidence Grade:
Moderate: controlled, double-blind design with biological measures, but small sample of infrequent users only.
Study Age:
Published in 2022.
Original Title:
Urinary Excretion Profile of Cannabinoid Analytes Following Acute Administration of Oral and Vaporized Cannabis in Infrequent Cannabis Users.
Published In:
Journal of analytical toxicology, 46(8), 882-890 (2022)
Database ID:
RTHC-04218

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled TrialGold standard for testing treatments
This study
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal Study

Participants are randomly assigned to treatment or placebo groups to test cause and effect.

What do these levels mean? →

Frequently Asked Questions

Why does oral cannabis produce higher urine concentrations?

When cannabis is eaten, it undergoes extensive first-pass metabolism in the liver, producing higher concentrations of detectable metabolites compared to inhaled cannabis, which enters the bloodstream more directly through the lungs.

Could vaping cannabis help avoid a positive drug test?

Not reliably. While vaporized cannabis produced fewer positives (59.5%) than oral (97.6%), the majority of vaporized sessions still triggered positive results at standard cutoffs.

What are the standard federal drug testing cutoffs?

The recommended federal workplace criteria use a 50 ng/mL immunoassay screening cutoff followed by a 15 ng/mL confirmation cutoff via LC-MS/MS for THC-COOH.

Read More on RethinkTHC

Cite This Study

RTHC-04218·https://rethinkthc.com/research/RTHC-04218

APA

Sholler, Dennis J; Zamarripa, C Austin; Spindle, Tory R; Martin, Erin L; Kuntz, David; Vandrey, Ryan; Grabenauer, Megan. (2022). Urinary Excretion Profile of Cannabinoid Analytes Following Acute Administration of Oral and Vaporized Cannabis in Infrequent Cannabis Users.. Journal of analytical toxicology, 46(8), 882-890. https://doi.org/10.1093/jat/bkac042

MLA

Sholler, Dennis J, et al. "Urinary Excretion Profile of Cannabinoid Analytes Following Acute Administration of Oral and Vaporized Cannabis in Infrequent Cannabis Users.." Journal of analytical toxicology, 2022. https://doi.org/10.1093/jat/bkac042

RethinkTHC

RethinkTHC Research Database. "Urinary Excretion Profile of Cannabinoid Analytes Following ..." RTHC-04218. Retrieved from https://rethinkthc.com/research/sholler-2022-urinary-excretion-profile-of

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.